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  To clarify factors affecting prognosis foliowing endocrine therapy， stage D2 patients who died
from prostatic cancer within 3 years and those under well－controlled state longer than 5 years
were compared with respect to background factors and response to endocrine therapy． Thirty－five
and 18 caseg．， respectively， were studied． Differences between the two groups were bone pain，
anemia， tumor grade， number of bone metastasis， and response to endocrine therapy． Performance
status in long－term survival groups tended to be better than that in short－term cancer death groups．，
                             （Acta Urol． Jpn． 36： 667－671， 1990）








































































Table 1． Characteristlc factors in host
































































































  Pattern Score 2－6
       7－10
  Secondary Pattern 1－3
         4， 5
  Worst Pattern 1－3
       4， 5
骨転移
転移骨数O～4
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